Global Opioid Induced Constipation Drugs
Market Report
2024
Opioid Induced Constipation Drugs Market Report 2024 (Global Edition)
As per Cognitive Market Research's latest published report, the Global Opioid Induced Constipation Drugs market size was USD 1.12 Billion in 2022 and it is forecasted to reach USD 1.75 Billion by 2030. Opioid Induced Constipation Drugs Industry's Compound Annual Growth Rate will be 4.57% from 2023 to 2030.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Opioid Induced Constipation Drugs Market Report 2024.
Global Opioid Induced Constipation Drugs Market Report 2024 Market Size Split by Drug Type (Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Chloride Channel-2 Activators, Mu-opioid R...
As per Cognitive Market Research's latest published report, the Global Opioid Induced Constipation Drugs market size was USD 1.12 Billion in 2022 and it is forecasted to reach USD 1.75 Billion by 2030. Opioid Induced Constipation Drugs Industry's Compound Annual Growth Rate will be 4.57% from 2023 to 2030.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Opioid Induced Constipation Drugs Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 4.57% |
| Market Split by Drug Type |
|
| Market Split by Distribution Channel |
|
| Market Split by Prescription Type |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Opioid Induced Constipation Drugs industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Opioid Induced Constipation Drugs Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Opioid Induced Constipation Drugs Market Report Description
What are Opioid Induced Constipation Drugs?
Opioid-induced constipation is caused by opioids, which stimulate enteric -receptors, rising tonic non-propulsive reductions in the large and small intestines, causing desiccation of stool and increasing colonic fluid absorption. The opioid-induced constipation drugs refer to several treatments and drugs, which are used to manage constipation caused by opioid use. In addition, these drugs are available and approved including chloride channel-2 activators, drugs showing surfactant effects, and mu-opioid receptor antagonists.
Factors Impacting Opioid Induced Constipation Drugs Market
Increasing demand for opioid-induced constipation drug management of opioid-induced constipation disorder and treatment is the key factor expected to drive the growth of the opioid-induced constipation drugs market. In addition, increasing awareness about the use of chloride channel type-2 activators and mu-opioid receptor antagonists are expected to drive the growth of the opioid-induced constipation drugs market.
Opioid-Induced Constipation Drugs Market Opportunities:
Increasing research and development activities, regulatory approvals, demand for therapeutics for treating opioid-induced constipation, and spending for opioid-induced constipation research create growth opportunities for the opioid-induced constipation drugs market in the forecast period.
Opioid-Induced Constipation Drugs Market Restraints:
The increasing cost of pharmaceuticals and side effects of using opioid-induced constipation drugs anticipated to hamper the growth of the opioid-induced constipation drugs market.
We have various report editions of Opioid Induced Constipation Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Opioid Induced Constipation Drugs Market Insights Video
Opioid-Induced Constipation Drugs Industry News:
In February 2021, RedHill Biopharma announced the agreement with Cosmo Pharmaceuticals for the manufacturing of Movantik and RHB-204 designed to treat opioid-induced constipation (OIC) in adult patients.
Top Companies Market Share in Opioid Induced Constipation Drugs Industry: (In no particular order of Rank)
- Ironwood Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- Pfizer
- Progenics Pharmaceuticals Inc
- Shionogi Co. Ltd
- Allergan Plc
- Nektar Therapeutics
- Purdue Pharma
- S.L.A. Pharma AG
- Mundipharma International Limited
- Ono Pharmaceutical Co. Ltd
- Takeda Pharmaceutical Company Limited
- Theravance Biopharma Inc
- Valeant Pharmaceuticals International
- Cosmo Pharmaceuticals SA
- Daewoong Pharmaceutical
- C.B. Fleet Company
- Sucampo Pharmaceuticals
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
The North America Opioid Induced Constipation Drugs Market dominates the overall market:
North America has the largest revenue share in the opioid-induced constipation drugs market. This is owing to the increasing occurrence of opioid-induced constipation cases and healthcare infrastructure advancement and the number of major players offering novel therapeutics in the region. This is anticipated to drive the growth of the opioid-induced constipation drugs market in the region.
The current report Scope analyzes Opioid Induced Constipation Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Opioid Induced Constipation Drugs Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
Opioid Induced Constipation Drugs Market Analysis
Global Opioid Induced Constipation Drugs Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Opioid Induced Constipation Drugs Industry growth. Opioid Induced Constipation Drugs market has been segmented with the help of its Drug Type, Distribution Channel Prescription Type, and others. Opioid Induced Constipation Drugs market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
By Type, the Mu-opioid Receptor Antagonists segment has the largest revenue share of Opioid Induced Constipation Drugs Market!
Based on drug type, the Mu-opioid receptor antagonists segment has the largest revenue share in the opioid-induced constipation drugs market. This is due to the increasing number of launches of products by the major players for the treatment of opioid-induced constipation and evaluating research activities for the efficacy and safety of agents. This is projected to drive the growth of this segment.
- Lubiprostone
- Methyl Naltrexone Bromide
- Naldemedine
- Alvimopan
- Chloride Channel-2 Activators
- Mu-opioid Receptor Antagonists
- Other
Opioid Induced Constipation Drugs Market Share (%) by Drug Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Opioid Induced Constipation Drugs Industry. Request a Free Sample PDF!
By Distributional Channel, the Drug Stores and Retail Pharmacies segment has the largest market share of Opioid Induced Constipation Drugs Market!
Based on distribution channels, the drug store and retail pharmacies segment has the largest market share in the opioid-induced constipation drugs market. This is attributed to the increasing preference of people for retail pharmacies and retail pharmacies guide patients about the use and medication during the treatment.
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Pharmacies
Opioid Induced Constipation Drugs Market Share (%) by Distribution Channel in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Opioid Induced Constipation Drugs market report 2024 Edition by contacting our team.
Opioid Induced Constipation Drugs Prescription Type Segment Analysis
Based on the prescription type, the prescribed drugs segment has the major revenue share in the opioid-induced constipation drugs market. This is owing to the increasing availability of key drugs and the number of key players manufacturing formulations likely to drive the growth of this segment.
- Prescribed Drugs
- Over The Counter Drugs
Author's Detail
Anushka GoreResearch Associate at Cognitive Market Research
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.
Anushka is a highly motivated and detail-oriented research analyst with a passion for uncovering valuable insights from data. Her expertise in Market Research and business intelligence has equipped her with the skills necessary to analyze complex information and provide strategic recommendations. She thrives in dynamic environments where her analytical abilities and research expertise can contribute to informed decision-making for businesses
I played a pivotal role in conducting market research and competitive analysis. I have a demonstrated ability to synthesize diverse data sources, identify trends, and translate findings into actionable recommendations. My collaborative approach facilitated effective communication of insights, fostering a data-driven culture within the organization. I am committed to maintaining excellence through continuous learning and staying ahead of industry trends. Regular participation in conferences and professional development opportunities keeps my skills sharp and relevant.
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Opioid Induced Constipation Drugs Market is witnessing significant growth in the near future.
In 2023, the Lubiprostone segment accounted for noticeable share of global Opioid Induced Constipation Drugs Market and is projected to experience significant growth in the near future.
The Hospital Pharmacies segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies Ironwood Pharmaceuticals Inc, Pfizer and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Frequently Asked Questions
Latest News about Opioid Induced Constipation Drugs Market
- http://www.trade.gov
- http://www.gov.uk
- http://www.fda.gov
- http://www.hhs.gov
- http://www.who.int
- http://www.bls.gov
- http://www.gao.gov
- http://www.ncbi.nlm.nih.gov
- http://www.healthcaredive.com
- http://www.export.gov
- http://www.weforum.org
- http://www.health.gov.za
- http://www.usaid.gov
- http://www.eumdr.com
- http://www.cdc.gov
- http://www.ama-assn.org
- http://www.washingtonpost.com
- http://www.ecfr.gov
- http://www.hbr.org
- http://www.worldbank.org
- http://www.commission.europa.eu
- http://www.cbi.eu
- http://www.unicef.org
- http://www.ecipe.org
- http://www.ema.europa.eu
Opioid Induced Constipation Drugs Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Drug Type | Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Chloride Channel-2 Activators, Mu-opioid Receptor Antagonists, Other |
| Distribution Channel | Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies |
| Prescription Type | Prescribed Drugs, Over The Counter Drugs |
| List of Competitors | Ironwood Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Pfizer, Progenics Pharmaceuticals Inc, Shionogi Co. Ltd, Allergan Plc, Nektar Therapeutics, Purdue Pharma, S.L.A. Pharma AG, Mundipharma International Limited, Ono Pharmaceutical Co. Ltd, Takeda Pharmaceutical Company Limited, Theravance Biopharma Inc, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, C.B. Fleet Company, Sucampo Pharmaceuticals |
This chapter will help you gain GLOBAL Market Analysis of Opioid Induced Constipation Drugs. Further deep in this chapter, you will be able to review Global Opioid Induced Constipation Drugs Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Opioid Induced Constipation Drugs Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Opioid Induced Constipation Drugs Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Opioid Induced Constipation Drugs Revenue Market Size By Region
-
-
1.3 Global Opioid Induced Constipation Drugs Market Size By Drug Type 2019 -2031
-
1.3.1 Lubiprostone Market Size
-
1.3.2 Methyl Naltrexone Bromide Market Size
-
1.3.3 Naldemedine Market Size
-
1.3.4 Alvimopan Market Size
-
1.3.5 Chloride Channel-2 Activators Market Size
-
1.3.6 Mu-opioid Receptor Antagonists Market Size
-
1.3.7 Other Market Size
-
-
1.4 Global Opioid Induced Constipation Drugs Market Size By Distribution Channel 2019 -2031
-
1.4.1 Hospital Pharmacies Market Size
-
1.4.2 Drug Store and Retail Pharmacies Market Size
-
1.4.3 Online Pharmacies Market Size
-
-
1.5 Global Opioid Induced Constipation Drugs Market Size By Prescription Type 2019 -2031
-
1.5.1 Prescribed Drugs Market Size
-
1.5.2 Over The Counter Drugs Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Drug Type
-
1.7.3 Global Market Revenue Split By Distribution Channel
-
1.7.4 Global Market Revenue Split By Prescription Type
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Opioid Induced Constipation Drugs Market Size 2019 - 2031
-
2.1.1 North America Opioid Induced Constipation Drugs Market Size By Country 2019 - 2031
-
2.1.2 North America Opioid Induced Constipation Drugs Market Size by Drug Type 2019 -2031
-
2.1.2.1 North America Lubiprostone Market Size
-
2.1.2.2 North America Methyl Naltrexone Bromide Market Size
-
2.1.2.3 North America Naldemedine Market Size
-
2.1.2.4 North America Alvimopan Market Size
-
2.1.2.5 North America Chloride Channel-2 Activators Market Size
-
2.1.2.6 North America Mu-opioid Receptor Antagonists Market Size
-
2.1.2.7 North America Other Market Size
-
-
2.1.3 North America Opioid Induced Constipation Drugs Market Size by Distribution Channel 2019 -2031
-
2.1.3.1 North America Hospital Pharmacies Market Size
-
2.1.3.2 North America Drug Store and Retail Pharmacies Market Size
-
2.1.3.3 North America Online Pharmacies Market Size
-
-
2.1.4 North America Opioid Induced Constipation Drugs Market Size by Prescription Type 2019 -2031
-
2.1.4.1 North America Prescribed Drugs Market Size
-
2.1.4.2 North America Over The Counter Drugs Market Size
-
-
-
2.2 Add-Ons: Customize the Report Edition
Purchase Add-Ons to Customize the Report Edition and get further granular data level data about the North America market. Add-On Cost: Request before placing the order, Respective Pricing will be informed after sending the inquiry
-
2.2.1 North America Company Market Share 2019 till 2023
-
2.2.2 Qualitative Analysis for North America Market
Qualitative Analysis for the North America Market: North America Opioid Induced Constipation Drugs Market Trends North America Opioid Induced Constipation Drugs Technological Road Map North America Opioid Induced Constipation Drugs Market Drivers North America Opioid Induced Constipation Drugs Market Restraints North America Opioid Induced Constipation Drugs Market Opportunity Market Attractiveness Analysis COVID – 19 Impact Analysis PESTEL Analysis Porter’s Five Forces Analysis Product Life Cycle Industrial Chain Analysis
-
-
2.3 Executive Summary North America Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary North America Market (2019 vs 2024 vs 2031)
-
2.3.1 North America Market Summary 2019 vs 2024 vs 2031
-
2.3.2 North America Market Revenue Split By Drug Type
-
2.3.3 North America Market Revenue Split By Distribution Channel
-
2.3.4 North America Market Revenue Split By Prescription Type
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Opioid Induced Constipation Drugs Market Size 2019 - 2031
-
3.1.1 Europe Opioid Induced Constipation Drugs Market Size By Country 2019 - 2031
-
3.1.2 Europe Opioid Induced Constipation Drugs Market Size by Drug Type 2019 -2031
-
3.1.2.1 Europe Lubiprostone Market Size
-
3.1.2.2 Europe Methyl Naltrexone Bromide Market Size
-
3.1.2.3 Europe Naldemedine Market Size
-
3.1.2.4 Europe Alvimopan Market Size
-
3.1.2.5 Europe Chloride Channel-2 Activators Market Size
-
3.1.2.6 Europe Mu-opioid Receptor Antagonists Market Size
-
3.1.2.7 Europe Other Market Size
-
-
3.1.3 Europe Opioid Induced Constipation Drugs Market Size by Distribution Channel 2019 -2031
-
3.1.3.1 Europe Hospital Pharmacies Market Size
-
3.1.3.2 Europe Drug Store and Retail Pharmacies Market Size
-
3.1.3.3 Europe Online Pharmacies Market Size
-
-
3.1.4 Europe Opioid Induced Constipation Drugs Market Size by Prescription Type 2019 -2031
-
3.1.4.1 Europe Prescribed Drugs Market Size
-
3.1.4.2 Europe Over The Counter Drugs Market Size
-
-
-
3.2 Add-Ons: Customize the Report Edition
-
3.2.1 Europe Company Market Share 2019 till 2023
-
3.2.2 Qualitative Analysis for Europe Market
-
-
3.3 Executive Summary Europe Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Europe Market (2019 vs 2024 vs 2031)
-
3.3.1 Europe Revenue Market Summary 2019 vs 2024 vs 2031
-
3.3.2 Europe Market Revenue Split By Drug Type
-
3.3.3 Europe Market Revenue Split By Distribution Channel
-
3.3.4 Europe Market Revenue Split By Prescription Type
-
Chapter 4 Asia-Pacific Market Analysis
-
4.1 Asia Pacific Opioid Induced Constipation Drugs Market Size 2019 - 2031
-
4.1.1 Asia Pacific Opioid Induced Constipation Drugs Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Opioid Induced Constipation Drugs Market Size by Drug Type 2019 -2031
-
4.1.2.1 Asia Pacific Lubiprostone Market Size
-
4.1.2.2 Asia Pacific Methyl Naltrexone Bromide Market Size
-
4.1.2.3 Asia Pacific Naldemedine Market Size
-
4.1.2.4 Asia Pacific Alvimopan Market Size
-
4.1.2.5 Asia Pacific Chloride Channel-2 Activators Market Size
-
4.1.2.6 Asia Pacific Mu-opioid Receptor Antagonists Market Size
-
4.1.2.7 Asia Pacific Other Market Size
-
-
4.1.3 Asia Pacific Opioid Induced Constipation Drugs Market Size by Distribution Channel 2019 -2031
-
4.1.3.1 Asia Pacific Hospital Pharmacies Market Size
-
4.1.3.2 Asia Pacific Drug Store and Retail Pharmacies Market Size
-
4.1.3.3 Asia Pacific Online Pharmacies Market Size
-
-
4.1.4 Asia Pacific Opioid Induced Constipation Drugs Market Size by Prescription Type 2019 -2031
-
4.1.4.1 Asia Pacific Prescribed Drugs Market Size
-
4.1.4.2 Asia Pacific Over The Counter Drugs Market Size
-
-
-
4.2 Add-Ons: Customize the Report Edition
-
4.2.1 Asia Pacific Company Market Share 2019 till 2023
-
4.2.2 Qualitative Analysis for Asia Pacific Market
-
-
4.3 Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
-
4.3.1 Asia Pacific Market Summary 2019 vs 2024 vs 2031
-
4.3.2 Asia Pacific Market Revenue Split By Drug Type
-
4.3.3 Asia Pacific Market Revenue Split By Distribution Channel
-
4.3.4 Asia Pacific Market Revenue Split By Prescription Type
-
Chapter 5 South America Market Analysis
-
5.1 South America Opioid Induced Constipation Drugs Market Size 2019 - 2031
-
5.1.1 South America Opioid Induced Constipation Drugs Revenue Market Size By Country 2019 - 2031
-
5.1.2 South America Opioid Induced Constipation Drugs Market Size by Drug Type 2019 -2031
-
5.1.2.1 South America Lubiprostone Market Size
-
5.1.2.2 South America Methyl Naltrexone Bromide Market Size
-
5.1.2.3 South America Naldemedine Market Size
-
5.1.2.4 South America Alvimopan Market Size
-
5.1.2.5 South America Chloride Channel-2 Activators Market Size
-
5.1.2.6 South America Mu-opioid Receptor Antagonists Market Size
-
5.1.2.7 South America Other Market Size
-
-
5.1.3 South America Opioid Induced Constipation Drugs Market Size by Distribution Channel 2019 -2031
-
5.1.3.1 South America Hospital Pharmacies Market Size
-
5.1.3.2 South America Drug Store and Retail Pharmacies Market Size
-
5.1.3.3 South America Online Pharmacies Market Size
-
-
5.1.4 South America Opioid Induced Constipation Drugs Market Size by Prescription Type 2019 -2031
-
5.1.4.1 South America Prescribed Drugs Market Size
-
5.1.4.2 South America Over The Counter Drugs Market Size
-
-
-
5.2 Add-Ons: Customize the Report Edition
-
5.2.1 South America Company Market Share 2019 till 2023
-
5.2.2 Qualitative Analysis for South America Market
-
-
5.3 Executive Summary South America Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary South America Market (2019 vs 2024 vs 2031)
-
5.3.1 South America Market Summary 2019 vs 2024 vs 2031
-
5.3.2 South America Market Revenue Split By Drug Type
-
5.3.3 South America Market Revenue Split By Distribution Channel
-
5.3.4 South America Market Revenue Split By Prescription Type
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Opioid Induced Constipation Drugs Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Opioid Induced Constipation Drugs Revenue Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Opioid Induced Constipation Drugs Market Size by Drug Type 2019 -2031
-
6.1.2.1 Middle East and Africa Lubiprostone Market Size
-
6.1.2.2 Middle East and Africa Methyl Naltrexone Bromide Market Size
-
6.1.2.3 Middle East and Africa Naldemedine Market Size
-
6.1.2.4 Middle East and Africa Alvimopan Market Size
-
6.1.2.5 Middle East and Africa Chloride Channel-2 Activators Market Size
-
6.1.2.6 Middle East and Africa Mu-opioid Receptor Antagonists Market Size
-
6.1.2.7 Middle East and Africa Other Market Size
-
-
6.1.3 Middle East and Africa Opioid Induced Constipation Drugs Market Size by Distribution Channel 2019 -2031
-
6.1.3.1 Middle East and Africa Hospital Pharmacies Market Size
-
6.1.3.2 Middle East and Africa Drug Store and Retail Pharmacies Market Size
-
6.1.3.3 Middle East and Africa Online Pharmacies Market Size
-
-
6.1.4 Middle East and Africa Opioid Induced Constipation Drugs Market Size by Prescription Type 2019 -2031
-
6.1.4.1 Middle East and Africa Prescribed Drugs Market Size
-
6.1.4.2 Middle East and Africa Over The Counter Drugs Market Size
-
-
-
6.2 Add-Ons: Customize the Report Edition
-
6.2.1 Middle East and Africa Company Market Share 2019 till 2023
-
6.2.2 Qualitative Analysis for Middle East and Africa Market
-
-
6.3 Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
-
6.3.1 Middle East and Africa Market Summary 2019 vs 2024 vs 2031
-
6.3.2 Middle East and Africa Market Revenue Split By Drug Type
-
6.3.3 Middle East and Africa Market Revenue Split By Distribution Channel
-
6.3.4 Middle East and Africa Market Revenue Split By Prescription Type
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Opioid Induced Constipation Drugs Market Size by Drug Type 2019 -2031
-
7.1.2 Country 1Opioid Induced Constipation Drugs Market Size by Distribution Channel 2019 -2031
-
7.1.3 Country 1Opioid Induced Constipation Drugs Market Size by Prescription Type 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Opioid Induced Constipation Drugs Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Ironwood Pharmaceuticals Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Daiichi Sankyo Co Ltd
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Pfizer
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Progenics Pharmaceuticals Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Shionogi Co. Ltd
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Allergan Plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Nektar Therapeutics
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Purdue Pharma
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 S.L.A. Pharma AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Mundipharma International Limited
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Ono Pharmaceutical Co. Ltd
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Takeda Pharmaceutical Company Limited
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Theravance Biopharma Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Valeant Pharmaceuticals International
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
8.2.15 Cosmo Pharmaceuticals SA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.15.2 Business Overview
-
8.2.15.3 Financials (Subject to data availability)
-
8.2.15.4 Product Types Specification
-
8.2.15.5 Business Strategy
-
8.2.15.6 S.W.O.TAnalysis
-
-
8.2.16 Daewoong Pharmaceutical
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.16.2 Business Overview
-
8.2.16.3 Financials (Subject to data availability)
-
8.2.16.4 Product Types Specification
-
8.2.16.5 Business Strategy
-
8.2.16.6 S.W.O.TAnalysis
-
-
8.2.17 C.B. Fleet Company
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.17.2 Business Overview
-
8.2.17.3 Financials (Subject to data availability)
-
8.2.17.4 Product Types Specification
-
8.2.17.5 Business Strategy
-
8.2.17.6 S.W.O.TAnalysis
-
-
8.2.18 Sucampo Pharmaceuticals
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.18.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.18.2 Business Overview
-
8.2.18.3 Financials (Subject to data availability)
-
8.2.18.4 Product Types Specification
-
8.2.18.5 Business Strategy
-
8.2.18.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Drug Type Analysis 2019 -2031, will provide market size split by Drug Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Drug Type Analysis 2019 -2031
-
10.1 Lubiprostone
-
10.1.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Lubiprostone 2019 -2031
-
-
10.2 Methyl Naltrexone Bromide
-
10.2.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Methyl Naltrexone Bromide 2019 -2031
-
-
10.3 Naldemedine
-
10.3.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Naldemedine 2019 -2031
-
-
10.4 Alvimopan
-
10.4.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Alvimopan 2019 -2031
-
-
10.5 Chloride Channel-2 Activators
-
10.5.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Chloride Channel-2 Activators 2019 -2031
-
-
10.6 Mu-opioid Receptor Antagonists
-
10.6.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Mu-opioid Receptor Antagonists 2019 -2031
-
-
10.7 Other
-
10.7.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Other 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Distribution Channel Analysis 2019 -2031
-
11.1 Hospital Pharmacies
-
11.1.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Hospital Pharmacies 2019 - 2031
-
-
11.2 Drug Store and Retail Pharmacies
-
11.2.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Drug Store and Retail Pharmacies 2019 - 2031
-
-
11.3 Online Pharmacies
-
11.3.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Online Pharmacies 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Prescription Type Analysis 2019 -2031
-
12.1 Prescribed Drugs
-
12.1.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Prescribed Drugs 2019 -2031
-
-
12.2 Over The Counter Drugs
-
12.2.1 Global Opioid Induced Constipation Drugs Revenue Market Size and Share by Over The Counter Drugs 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Opioid Induced Constipation Drugs market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Anushka Gore and Team
- 1.1 Opioid Induced Constipation Drugs Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Opioid Induced Constipation Drugs Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Opioid Induced Constipation Drugs Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Opioid Induced Constipation Drugs Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Opioid Induced Constipation Drugs Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Opioid Induced Constipation Drugs Market
Key Questions Answered By Opioid Induced Constipation Drugs Market Report 2024
| Why Lubiprostone have a significant impact on Opioid Induced Constipation Drugs market? |
| What are the key factors affecting the Lubiprostone and Methyl Naltrexone Bromide of Opioid Induced Constipation Drugs Market? |
| What is the CAGR/Growth Rate of Hospital Pharmacies during the forecast period? |
| By type, which segment accounted for largest share of the global Opioid Induced Constipation Drugs Market? |
| Which region is expected to dominate the global Opioid Induced Constipation Drugs Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
